NEW YORK (GenomeWeb News) - Arthur Holden plans to leave his post as vice president of corporate and market development at Illumina in mid-October, the company said this week in a filing with the US Securities and Exchange Commission.
 
Holden is director of the Serious Adverse Events Consortium, a pharma-backed initiative announced this week that aims to find genetic causes for severe adverse events that hamper drug development.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.